PPD Clause Samples

The PPD (Prepaid Payment Directive) clause establishes the terms under which payments are made in advance for goods or services. Typically, this clause outlines the timing, method, and conditions for prepayment, such as requiring a certain percentage of the contract price to be paid before delivery or commencement of work. By specifying these requirements, the PPD clause ensures that the seller or service provider receives funds upfront, reducing their financial risk and providing assurance of the buyer's commitment.
POPULAR SAMPLE Copied 1 times
PPD. The spousor's raudomisatiou mauager will keep the master lists. A copy of the list of treatment numbers (Lists B and C) will be confidentially supplied to the Chemistry Manufacturing and to the Contract Research Organisation (CRO) in charge of IRT. Similarly, a copy of the list of randomisation numbers (List A) will also be confidentially supplied to the CRO in charge of IRT will be kept confidential in a secure location. Access to the randomisation lists must be restricted until authorisation is given to release them for final analysis.
View Source
PPD. The Buyer may avail of the PPD equivalent to one percent (1%) of the total of the Capacity and Energy Charges and other components of the current power bill, provided that: i. The Buyer has no arrears from previous power ▇▇▇▇▇▇▇▇ including the Security Deposit or any unpaid charges or penalties including VAT; ii. The Buyer has submitted all necessary Bureau of Internal Revenue (BIR) Tax Certificates for all taxes withheld; lll. The Buyer pays the power bill in full on or before the 10th day of the calendar month following the current Billing Period; and
View SourceView Similar (2)
PPD poskytovatel a hlavní zkoušející budou uchovávat totožnost subjektů v tajnosti a dodrží veškeré platné předpisy týkající se utajení jejich totožnosti a jejich zdravotních záznamů.
View Source
PPD. The sponsor’s randomisation manager will keep the master lists. A copy of the list of treatment numbers (Lists B and C) will be confidentially supplied to the Chemistry Manufacturing and the Contract Research Organisation (CRO) in charge of IRT. Similarly, a copy of the list of randomisation numbers (List A) will also be confidentially supplied to the CRO in charge of IRT will be kept confidential in a secure location. Access to the randomisation lists must be restricted until authorisation is given to release them for final analysis.
View Source
PPD. The determination of severity not listed in the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DHHS 2017) should be made by the investigator based upon medical judgment and the definitions of severity as follows: • Grade 1 (Mild): Mild symptoms causing no or minimal interference with usual social and functional activities with no intervention indicated • Grade 2 (Moderate): Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated • Grade 3 (Severe): Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated • Grade 4 (Potentially life-threatening): Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death • Grade 5 (Death) Changes in the severity of an AE should be documented to allow the duration of the event at each level of intensity to be assessed. An AE characterized as intermittent does not require documentation of the onset and duration of each episode.
View Source
PPD. PPD shall indemnify and hold ▇▇▇▇▇▇▇▇▇▇ harmless from any loss ---- expense (including counsel fees), cost, liability, damage or claim for personal injuries, including death at any time resulting therefrom, or for damage to property arising out of or in connection with the performance of this Agreement (hereinafter collectively "▇▇▇▇▇▇▇▇▇▇ Loss") and resulting from: 1) the failure of the PPD or Investigators or their employees or agents to perform the Study in accordance with the Protocol or in a manner required of a reasonable and prudent clinical investigator or physician; or 2) the negligence or willful misconduct of PPD or the employees, agents or any other persons connected with PPD or its performance hereunder, including Investigators, except to the extent such ▇▇▇▇▇▇▇▇▇▇ Loss is due to the negligence of ▇▇▇▇▇▇▇▇▇▇.
View Source
PPD. (a) Subject to Section 9.1(b), PPD shall not, except pursuant to the Collaboration for use in the Field, (i) discover, develop, or commercialize any Inhibitor of the Target or any products containing or derived from such Inhibitors, (ii) acquire from any Third Party the right to discover, develop, or commercialize one or more Inhibitors of the Target outside the Collaboration, (iii) enter into any agreement in which any Third Party pursuant to such agreement discovers, develops, or commercializes one or more Inhibitors of the Target, or (iv) invest in any Third Party that, at the time such investment is made, is engaged or intends to engage in the discovery, development or commercialization of one or more Inhibitors of the Target. (b) Notwithstanding Section 9.1(a), PPD may provide services to Third Parties in connection with the preclinical and clinical development of one or more Inhibitors of the Target and products containing or comprising such inhibitors, provided that: (i) such services are limited to those that are usual and customary for clinical research organizations in general and PPD in particular; (ii) those PPD employees who perform formulation work pursuant to this Agreement (1) shall not perform for any Third Party any formulation work upon any Inhibitor of the Target and (2) shall not advise, or disclose any formulation related Information generated in the course of the Collaboration to, any PPD employee performing for any Third Party any formulation work upon any Inhibitor of the Target; and (iii) PPD shall not retain (1) any right, title, interest or license in any such Inhibitor; or (2) any right to receive (directly or indirectly) any consideration in connection with the subsequent development, regulatory filings, regulatory approval, promotion or sales of such Inhibitors or products (other than normal and customary fees and expenses charged by PPD for any such services).
View Source

Related to PPD

  • Licensee “Licensee” means the individual or company that has entered into an Agreement with the Embassy. “Offer” means a response to a solicitation that, if accepted, would bind the offeror to perform the resultant Agreement.

  • Licensor any Person from whom a Grantor obtains the right to use any Intellectual Property. Lien: any Person’s interest in Property securing an obligation owed to, or a claim by, such Person, whether such interest is based on common law, statute or contract, including liens, security interests, pledges, hypothecations, statutory trusts, reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, and other title exceptions and encumbrances affecting Property. Lien Waiver: an agreement, in form and substance satisfactory to Collateral Agent, by which (a) for any material Collateral located on leased premises, the lessor waives or subordinates any Lien it may have on the Collateral, and agrees to permit Collateral Agent to enter upon the premises and remove the Collateral or to use the premises to store or dispose of the Collateral; (b) for any Collateral held by a warehouseman, processor, shipper, customs broker or freight forwarder, such Person waives or subordinates any Lien it may have on the Collateral, agrees to hold any Documents in its possession relating to the Collateral as agent for Collateral Agent, and agrees to deliver the Collateral to Collateral Agent upon request; (c) for any Collateral held by a repairman, mechanic or bailee, such Person acknowledges Collateral Agent’s Lien, waives or subordinates any Lien it may have on the Collateral, and agrees to deliver the Collateral to Collateral Agent upon request; and (d) for any Collateral subject to a Licensor’s Intellectual Property rights, the Licensor grants to Collateral Agent the right, vis-à-vis such Licensor, to enforce Collateral Agent’s Liens with respect to the Collateral, including the right to dispose of it with the benefit of the Intellectual Property, whether or not a default exists under any applicable License.

  • Sublicensees 4.1 The Regents also grants to IntraBiotics the right to issue exclusive or nonexclusive sublicenses ("Sublicenses") to third parties to make, have made, use and sell [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. Licensed Products and to practice Licensed Methods in the Field in any jurisdiction under which IntraBiotics has exclusive rights under this Agreement. All such Sublicenses shall be subject to the rights of The Regents under this Agreement, with the exception that Sublicensees need not pay the license issue fee provided for in Article 5, or patent costs provided for in Article 8. To the extent that IntraBiotics licenses third parties to make, have made, use and sell Licensed Products and to practice Licensed Methods that are covered solely by Joint Patent Rights, for the purposes of this Agreement, such licenses shall be considered Sublicenses. To the extent applicable, Sublicenses shall also be subject to the rights of the United States federal government under 35 U.S.C. Section 201-212. 4.2 IntraBiotics shall pay to The Regents, upon the Net Sales of Licensed Products sold or disposed of by Sublicensees, an earned royalty equal to [ * ] of the royalties received by IntraBiotics from its Sublicensees for products covered by Regents' Patent Rights, and an earned royalty equal to [ * ] for products covered solely by Joint Patent Rights. 4.3 IntraBiotics shall pay to The Regents [ * ] of all Sublicensing Income. Such payments shall be made quarterly in accordance with the payment schedule described in paragraph 10.3. 4.4 IntraBiotics shall provide to The Regents a copy of each Sublicense granted by IntraBiotics and a copy of all information submitted to IntraBiotics by Sublicensees relevant to the computation of the payments due from IntraBiotics to The Regents under this Article 4. 4.5 IntraBiotics shall use its best efforts to write its sublicense agreements so that upon termination of this Agreement for any reason, all outstanding Sublicenses will be assigned to The Regents and will remain in full force and effect under the same terms and conditions with The Regents as the licensor thereunder in the stead of IntraBiotics, but the duties of The Regents under such assigned Sublicenses shall not be greater than the duties of The Regents under this Agreement.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Cornerstone shall use its best efforts to register or qualify such shares under such other securities or "blue sky" laws of such jurisdictions as the LLC reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable the LLC to consummate the disposition in such jurisdictions of the Registered Shares (provided that Cornerstone shall not be required to (i) qualify generally to do business in any jurisdiction in which it would not otherwise be required to qualify but for this Section 6.9, (ii) subject itself to taxation in any such jurisdiction, or (iii) consent to general service of process in any such jurisdiction).